Tenax Therapeutics to Present at H.C. Wainwright 21st Annual Global Investment Conference
29 August 2019 - 10:00PM
Business Wire
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty
pharmaceutical company focused on identifying, developing and
commercializing products that address cardiovascular and pulmonary
diseases with high unmet medical need, today announced that
management is scheduled to present and conduct one-on-one meetings
at the H.C. Wainwright 21st Annual Global Investment Conference to
be held in New York, NY on September 8th-10th. Anthony DiTonno,
Chief Executive Officer, is scheduled to present on Tuesday,
September 10th at 2:10 p.m. Eastern Time.
About Tenax Therapeutics Tenax Therapeutics, Inc., is a
specialty pharmaceutical company focused on identifying, developing
and commercializing products that address cardiovascular and
pulmonary diseases with high unmet medical need. The Company has a
world-class scientific team including recognized global experts in
pulmonary hypertension. The Company owns the North American rights
to develop and commercialize levosimendan and is currently
enrolling their Phase 2 clinical trial for the use of levosimendan
in the treatment of Pulmonary Hypertension associated with Heart
Failure and preserved Ejection Fraction (PH-HFpEF). For more
information, visit www.tenaxthera.com.
About Levosimendan Levosimendan is a calcium sensitizer
that works through a unique triple mechanism of action. It
initially was developed for intravenous use in hospitalized
patients with acute decompensated heart failure. It was discovered
and developed by Orion Pharma, Orion Corporation of Espoo Finland,
and is currently approved in over 60 countries for this indication
and not available in the United States. Tenax Therapeutics acquired
the North American rights to develop and commercialize levosimendan
from Phyxius Pharma, Inc.
Caution Regarding Forward-Looking Statements This news
release contains certain forward-looking statements by the Company
that involve risks and uncertainties and reflect the Company’s
judgment as of the date of this release. The forward-looking
statements are subject to a number of risks and uncertainties,
including, but not limited to matters beyond the Company’s control
that could lead to delays in the clinical study, new product
introductions and customer acceptance of these new products;
matters beyond the Company’s control that could impact the
Company’s continued compliance with Nasdaq listing requirements;
the impact of management changes on the Company’s business and
unanticipated charges, costs and expenditures not currently
contemplated that may occur as a result of management changes; and
other risks and uncertainties as described in the Company’s filings
with the Securities and Exchange Commission, including in its
annual report on Form 10-K filed on April 1, 2019, its quarterly
report on Form 10-Q filed on August 14, 2019 as well as its other
filings with the SEC. The Company disclaims any intent or
obligation to update these forward-looking statements beyond the
date of this release. Statements in this press release regarding
management’s future expectations, beliefs, goals, plans or
prospects constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190829005088/en/
Investor Contact: Westwicke, an ICR company Stephanie
Carrington, 646-277-1282 Stephanie.Carrington@icrinc.com
Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From Apr 2024 to May 2024
Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From May 2023 to May 2024